Ghayas C. Issa - Concepedia

Author

Ghayas C. Issa

The University of Texas MD Anderson Cancer Center ORCID

Also Known As

Adolfo de la Fuente Burguera, G. C. Issa, G. Issa, Ghayas C Issa, Ghayas C. Issa, Ghayas Issa, Ghufran S. Issa, Issa, Ghayas C., Koichi Takahashi, Koji Sasaki

452

Publications

7.4K

Citations

H-Index

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center Memorial Sloan Kettering Cancer Center Albert Einstein College of Medicine University of Chicago Washington University in St. Louis

About

Ghayas C. Issa is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, oncology, and hematology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	19	24	1.3K
2	Health Sciences	13	15	800
3	Cell Biology	5	5	149
4	Natural Sciences	1	1	14
5	Blood Transplantation	1	1	52

Ghayas C. Issa

105

Publications

5.7K

Citations

H-Index

Page 1

	Year	Citations
The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia Ghayas C. Issa, Ibrahim Aldoss, John F. DiPersio, Nature	2023	420
10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial Courtney D. DiNardo, Abhishek Maiti, Caitlin R. Rausch, The Lancet Haematology Hematological MalignancyMedicineMixed-phenotype Acute LeukemiaHematologyClinical Trials	2020	325
Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia Courtney D. DiNardo, Curtis A. Lachowiez, Koichi Takahashi, Journal of Clinical Oncology	2021	321
Impact of complete molecular response on survival in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia Nicholas J. Short, Elias Jabbour, Koji Sasaki, Blood	2016	246
Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial Elias Jabbour, Nicholas J. Short, Nitin Jain, The Lancet Haematology Hematological MalignancyLymphoid NeoplasiaMedicineHematologyImmunology	2022	215
Hyper‐CVAD plus ponatinib versus hyper‐CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia: A propensity score analysis Koji Sasaki, Elias Jabbour, Farhad Ravandi, Cancer	2016	195
Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience Kamal Chamoun, Hagop M. Kantarjian, Rami Atallah, Journal of Hematology & Oncology	2019	173
Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients Preetesh Jain, Hagop M. Kantarjian, Ahmad Ghorab, Cancer	2017	160
Menin Inhibition With Revumenib for <i>KMT2A</i> -Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101) Ghayas C. Issa, Ibrahim Aldoss, Michael J. Thirman, Journal of Clinical Oncology	2024	136
Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory <i>FLT3</i>-Mutated AML Nicholas J. Short, Naval Daver, Courtney D. DiNardo, Journal of Clinical Oncology	2024	120

Page 1